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Abstract
Background: Calcium kidney stones are common and recurrences are often not pre-
ventable by available empiric remedies. Their etiology is multifactorial and poly-
genic, and an increasing number of genes are implicated. Their identification will 
enable improved management.
Methods: DNA from three stone- formers in a Southampton family (UK) and two 
from an Italian family were analyzed independently by whole exome sequencing and 
selected variants were genotyped across all available members of both pedigrees. A 
disease variant of SLC25A25 (OMIM 608745), encoding the mitochondrial ATP- Mg/
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1 |  INTRODUCTION
Renal stones are aggregates of inorganic and/or organic crys-
tals formed within the kidneys. They are common worldwide 
with recent estimated lifetime prevalence in men of around 
10%. They often recur and this may impact significantly on 
the lives of stone formers. More than 75% are calcium oxa-
late stones, often mixed with calcium phosphate. Most of 
these are idiopathic. Many factors contribute to their forma-
tion, notably an increased concentration of minerals due to 
low fluid intake or dietary excesses, hormonal imbalance, 
and decreased protection by endogenous inhibitory agents in 
urine (Coe et al., 2005; Moe, 2006; Prochaska et al., 2016; 
Walker et al., 2013). These factors are variable and change 
throughout life. However, there is also an underlying genetic 
component, with heritability estimated at about 50%. Around 
20% of stone formers have a positive family history of stones 
compared with 6% among non- stone formers (Coe et al., 2005; 
Curhan et al., 1997; Gambaro et al., 2016; Goldfarb et al., 
2019; Walker et al., 2013). Well- established monogenic causes 
of stone disease are being recognized increasingly in individ-
uals referred to specialist clinics because of significant stone 
problems without a previous genetic diagnosis (Braun et al., 
2016; Daga et al., 2018; Gambaro et al., 2016; Halbritter et al., 
2015; Sayer, 2017; Vezzoli et al., 2011). However, in the ma-
jority of stone formers, genetic susceptibility is polygenic with 
co- inheritance of multiple small effect gene variants. GWAS 
studies have identified common polymorphisms (MAF > 1%) 
in 31 genes associated with stone formation, most with mod-
est effects (OR < 1.5; Howles & Thakker, 2020; Moe, 2006; 
Palsson et al., 2019). In other complex polygenic disorders 
such as diabetes mellitus, common polymorphisms do not fully 
account for genetic susceptibility. Rare/low- frequency variants 
are likely to contribute to the missing genetic component (Pang 
et al., 2021). Current interventions to prevent stone recurrence 
are still largely empiric and often ineffective (Gambaro et al., 
2016). Progress with targeted treatment and prevention de-
mands a better understanding of the underlying genetic factors.
Two decades ago, we undertook a small study in 
Southampton to look for variants in genes relevant to stones 
in 14 kindreds in which at least three first- degree relatives 
had had calcium stones (Walker & Griffin, 2015). Family 
members had biochemical investigation for stone risk fac-
tors. Mouthwash DNA was analyzed using microsatellites to 
investigate the segregation of four genes with stone forma-
tion (Vitamin D Receptor (VDR; OMIM 601769), Calcium 
Sensing Receptor (CASR; OMIM 601199), Thiazide- sensitive 
Sodium Chloride Transporter (SLC12A3; OMIM 600968) 
and Sodium Phosphate Transporter 2a (SLC34A1 OMIM 
182309). The results were negative. Many other studies have 
looked for polymorphisms in candidate genes known to in-
fluence urine composition which might increase the risk for 
stones. No common clear leaders have emerged (Palsson 
et al., 2019; Sayer, 2017; Vezzoli et al., 2011; Walker, 2019).
With whole exome sequencing (WES) and genome- wide 
association studies (GWAS), there is the potential to extend 
the search to the wide range of intracellular proteins that un-
derpin urine production (Howles et al., 2019; Palsson et al., 
2019; Tanikawa et al., 2019; Walker, 2019). In order to look 
further for gene variants responsible for increasing risk for 
kidney stones in these families, we have now analyzed blood 
stored from the study by WES.
A heterozygous dominant rare variant in the gene 
SLC25A25 (Solute Carrier Family 25  member 25) was 
Pi carrier 3 (APC3) was identified, and analyzed structurally and functionally with 
respect to its calcium- regulated transport activity.
Results: All five patients had a heterozygous dominant SLC25A25 variant 
(rs140777921; GRCh37.p13: chr 9 130868670 G>C; p.Gln349His; Reference 
Sequence NM_001006641.3). Non- stone formers also carried the variant indicating 
incomplete penetrance. Modeling suggests that the variant lacks a conserved polar 
interaction, which may cause structural instability. Calcium- regulated ATP transport 
was reduced to ~20% of the wild type, showing a large reduction in function.
Conclusion: The transporter is important in regulating mitochondrial ATP produc-
tion. This rare variant may increase urine lithogenicity through impaired provision 
of ATP for solute transport processes in the kidney, and/or for purinergic signaling. 
Variants found in other genes may compound this abnormality.
K E Y W O R D S
calcium kidney stones, calcium signaling, mitochondrial adenine nucleotide metastasis, 
mitochondrial transporter, purinergic signaling
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identified in stone formers in one Southampton kindred. 
This encodes the mitochondrial ATP- Mg/Pi carrier 3, APC3 
(aliases SCaMC2 [small calcium- binding mitochondrial car-
rier 2], and SLC25A25 [solute carrier family 25 member 25] 
[del Arco & Satrústegui, 2004; Fiermonte et al., 2004]). The 
same variant was identified independently in an Italian pedi-
gree, and segregated well with stone formation.
2 |  PATIENTS AND METHODS
2.1 | The families
The Southampton family was initially recruited to our study 
in 1998. Seven individuals spanning three generations were 
stone formers (3 deceased; Figure 1a). The propositus (II- 1), 
a 79- year- old patient of the Southampton stone clinic had her 
first stone aged 44  years and another, containing calcium, 
oxalate, and phosphate, at 78  years. Her mother (I- 4) had 
a nephrectomy for stones aged 39 years. Four other family 
members had renal stones aged 18– 64 years. A further male 
patient (II- 6) is not known to have had kidney stones but 
formed 2 cm bladder calculus on an indwelling catheter for 
Parkinson's disease. Twelve adults ≥18 years of age provided 
blood and urine for biochemical investigations and blood and 
mouth wash samples for DNA analysis. None of the family 
had primary hyperparathyroidism or, with the exception of 
patient II- 6, another underlying medical disorder associated 
with urinary tract stones. At the time of consenting to the fol-
low- up study in 2016, the participants were asked to complete 
a short questionnaire (Document S1) asking whether they had 
formed more stones, had chronic illnesses, repeat medications 
and whether any of their children or grandchildren had had 
kidney stones. In addition, their records held on the hospi-
tal computer system were reviewed for relevant clinical and 
biochemical data. DNA extracted from blood stored at −20℃ 
from stone formers II- 1, III- 5, and III- 7 was analyzed by 
WES. Segregation of selected rare variants with stones was 
investigated by genotyping DNA from all 12 participants.
The propositus in the family from Southern Italy sought 
counselling aged 51 years because of recurrent stones, hav-
ing had three removed from 32 years of age. He was phys-
ically very active and otherwise healthy, with no history of 
hypertension or diabetes and was not taking medications. His 
mother (I- 3 in Figure 1b), maternal uncle (I- 4, 76 years), and 
youngest son (III- 3, 21 years) had one or more kidney stones. 
From family members and contacts with general practitioners 
another five related subjects were identified spanning three 
generations, four still alive in 2016 (I- 7, II- 5, II- 7, and III- 8) 
and one deceased (I- 9). Through consultation of parish and 
civil registers of births and marriages the family was found to 
have two branches with the common ancestors born in 1888 
and 1891. All participants provided a blood sample or buccal 
swab for genotyping. Samples from II- 2 and III- 3 were ana-
lyzed by WES and the SLC25A25 mutation was confirmed by 
Sanger sequencing. Candidate variant alleles were genotyped 
in the pedigree using endonuclease restriction analysis.
2.2 | Biochemical investigations in 
Southampton 1998: derived values
Using creatinine clearance as a surrogate for inulin clearance 
and glomerular filtration rate, and 60% of albumin- corrected 
serum calcium for ultrafilterable calcium, approximate val-
ues for (a) fasting tubular reabsorption of Ca was estimated 
from the paired fasting blood and random urine samples: 
1- Ca clearance/creatinine clearance  ×  100%; [=1−urine 
Ca  ×  plasma creatinine/urine creatinine  ×  plasma ultrafil-
terable Ca × 100%], and (b) percent of Ca reabsorbed over 
24 hr = Ca reabsorbed/Ca filtered over 24 hr × 100%, where 
filtered Ca (mmol/24 hr) = ultrafilterable Ca x creatinine clear-
ance (L per 24 hr) and reabsorbed Ca = filtered- 24 hr urine Ca 
(mmol/24 hr). To assess tubular phosphate reabsorption, the 
renal threshold phosphate concentration (TmPO4/GFR) was 
estimated from paired fasting blood and urine samples using 
a nomogram (Walker & Griffin, 2015; Walker et al., 2013).
2.3 | Gene analyses
2.3.1 | Exome sequencing
In Southampton: Extracted DNA was assessed for quality 
and analyzed by WES. Library capture was performed using 
the Agilent SureSelect All Exon V.5 and sequenced using 
Illumina HiSeq platform. Raw sequence data were analyzed 
using a local pipeline for sequence alignment to human ge-
nome hg19/GRCh 37. To maximize sensitivity, variants 
for individual samples were called contemporaneously in 
Samtools v1.3.2 and GATK (v3.6) HaplotypeCaller. The re-
sultant merged VCF files were annotated using ANNOVAR 
(2015 Dec 14 release). The sequences were first cross- 
referenced against a panel of 366  genes relevant to stones 
which we extracted from published data (Table S1). Variants 
were then excluded if: they were common (minor allele fre-
quency (MAF) >0.02 in the 1000 Genome project); present 
in homopolymer tracts or repeat regions; had read depth 
<10; were located in highly mutable genes; had a strand- , or 
base quality bias and; were not identified in all three stone 
formers. This analysis was followed by more aggressive fil-
tering of data outside the 366 gene- panel with exclusion of 
synonymous, non- frameshift insertion or splicing or ncRNA 
splicing variants, or those with frequency of >2% in the in- 
house Southampton database of around 600 individual ex-
omes. All remaining variants were then prioritized through 
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F I G U R E  1  Pedigrees of the two families showing apparent autosomal dominant inheritance of stones. (a) UK family: DNA from individuals 
II- 1, III- 5, and III- 7 were analyzed by WES; segregation of the variant in the family was by KASPar genotyping. (b) Italian kindred: The left and 
the right branch of the pedigree trace their ancestry to a common family founder, indicated by the dashed lines. DNA from individuals II- 2, III- 3 
were analyzed by WES and the variant confirmed by Sanger sequencing. Segregation of the variant was by restriction analysis; Solid symbols: 
stone formers; Δ- miscarriages
   | 5 of 14JABALAMELI Et AL.
multidisciplinary team discussion according to rarity (EXAC, 
1000 Genomes), predicted pathogenicity (SIFT, site conser-
vation [Gerp++, Phylop scores]) and likely clinical relevance.
In Italy: WES was undertaken by the Centre for Applied 
Genomics (TCAG; Toronto, Ontario, Canada). Paired end 
sequencing of DNA fragments (average 200 bp) was carried 
out using the HiSeq 2500 platform (Illumina Inc.,). Sequence 
reads were trimmed using Trimmomatic (Bolger et al., 
2014) and aligned to the reference human genome sequence 
(hg19/GRCh 37). Single nucleotide variants and indels were 
called using GATK haplotype caller v. 3.2.2. (DePristo et al., 
2011). Variants were filtered to identify rare polymorphisms 
using publicly available databases (1,000 Genomes; Exome 
Aggregation Consortium [ExAC] browser, NHLBI Exome 
Sequencing Project [ESP], and dbSNP).
2.3.2 | Genotyping
In Southampton, selected variants were analyzed for segrega-
tion across all available family members using KASPar geno-
tying (KASP TM; LGC, Hoddesdon). In Italy, the c.1047G>C 
variant (transcript reference sequence NM_001006641.3) was 
confirmed in the proband (II- 2) and his son (III- 3) by bidirec-
tional Sanger sequencing of the PCR- amplified SLC25A25 
primers 3′- CTGCTCCTGTTGTGCAGGT- 5′ (forward; Tm 
60℃) and 3′- TGCTGGGAGGAGGTTTCTAA- 5′ (reverse; 
Tm 59.8℃). Other family members were genotyped by re-
striction analysis of the 227- bp PCR amplicon with BsrI or 
RsaI (New England Biolabs) whose restriction sites are abol-
ished by the c.1047G>C transversion.
2.4 | Computational modeling of APC3b
Models of the APC3 isoform b, APC3b, were generated in 
MODELLER (Webb & Sali, 2014), using the bovine mito-
chondrial ADP/ATP carrier (adenine nucleotide translocase) 
AAC1 (PDB: 1okc) and the fungal ADP/ATP carrier structures 
(PDB:4c9g, 4c9h, 4c9j, 4c9q) as templates (Pebay- Peyroula 
et al., 2003; Ruprecht et al., 2014). The structure of the calcium- 
regulatory domain was taken from PDB:4zcu (Harborne et al., 
2015). Models were visualized and the most likely rotamer for 
the histidine substitution at position 349 was selected in PyMOL 
Molecular Graphics System, Version 1.8 (Schrödinger LLC).
2.5 | Expression, purification, and 
functional characterization of wild- type and 
mutant APC3b
The human wild- type APC3b and the disease variant were 
expressed in yeast mitochondria, purified, analyzed by 
thermal stability assays and reconstituted, as described 
previously (Hofherr et al., 2018). Briefly, purified protein 
(~60  μg) was reconstituted into liposomes containing L- α- 
phosphatidylcholine (Avanti Polar Lipids) and tetraoleoyl 
cardiolipin (Avanti Polar Lipids) in a 20:1 (w/w) ratio. The 
detergent pentaethylene glycol monodecyl ether was added 
to a final concentration of 1.6% (v/v) to solubilize the lipids, 
and the detergent was removed by multiple additions of SM- 2 
bio- beads (Bio- Rad) in the presence of 1 mM ATP- Mg. The 
external substrate was removed using a PD10 desalting col-
umn (GE Healthcare). Transport rates were determined by 
measuring the uptake of 2 μM [14C]- ATP with or without the 
addition of 1 mM CaCl2 over a 15- min time- course. Uptake 
curves were fitted with a One- Phase Association model 
(GraphPad, Prism).
2.6 | Protein analysis
Proteins were separated using precast 4%– 12% TruPAGE™ 
SDS– PAGE gels (Merck KGaA), loaded with 5 µg of pro-
tein at 3:1 mix of sample to loading buffer and stained using 
InstantBlue™ Coomassie (Merck KGaA). Protein concen-
tration was determined by measuring the absorbance at 
280 nm using a NanoDrop ND- 1000 Spectrophotometer 
(NanoDropTechnologies).
2.7 | UK Biobank search for the selected 
rare gene variants
UK Biobank is a prospective cohort study to investigate risk 
factors for the major diseases of middle and old age. Between 
2006 and 2010 the study recruited around 500,000 men and 
women aged 40– 69 years who have had whole genome gen-
otyping undertaken and allowed linkage of their data with 
their medical records (Collins, 2012). A genome- wide asso-
ciation study of renal stone disease has recently been under-
taken in UK Biobank from 6,536 stone formers (66.7% men) 
and 388,508 controls (45.5% men) of white British ancestry, 
mean ages (SD) 67.9 (7.63) years and 66.8 (8.01) years, re-
spectively (Howles et al., 2019).
We sought to compare the population frequencies of 
the six variants prioritized from the Southampton WES 
data (SLC25A25, VPS16, PLA2R1, MAP3K5, PKP4, and 
HAVCR1) in the 6,536 Biobank stone formers and 388,508 
non- stone formers from the GWAS. Genotype data were 
available for five out of six of these variants (all except the 
HAVCR1 variant, which was not present on the UK Biobank 
Axiom array). Minor allele frequencies were compared 
for stone formers versus non- stone formers using PLINK, 
a tool for GWAS and population- based linkage analysis 
(Purcell et al., 2007), and a chi- squared test was performed. 
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A Bonferroni correction was applied to account for multiple 
testing, with the significance threshold set at p < .01 (0.05/5).
3 |  RESULTS
3.1 | Follow- up of Southampton patients
From the questionnaire in 2016, no new stone formers were 
identified in the family and none of the children of generation 
IV had had stones. From the participants and hospital records, 
three family members (I- 4, II- 3, and III- 5) had gallstones, one 
had developed diabetes mellitus, and five had hypertension. 
None had chronic muscle problems, but on separate courses 
of two statins for polygenic hyperlipidemia, one participant 
had muscle pains. There were no results available for creatine 
kinase during these events (Table S2).
3.2 | Biochemical assessment in 1998: 
Southampton family
The frequent biochemical risk factor identified in 1998 was 
a decrease in renal phosphate reabsorption, (“hyperphos-
phaturia”) in 6 of 12 participants (renal threshold phosphate 
concentration, TmPO4/GFR <0.80 mmol/L; Table S3). Only 
one individual (IV- 6) had an increased 24 hr urine calcium 
excretion, and across the pedigree calcium was reabsorbed 
well from the kidneys, exceeding 97% in all but two of the 12 
participants (II- 6 and IV- 6) over 24 hr, and in one (II- 6) when 
fasting. Patient II- 6 had an indwelling catheter and bladder 
stone.
3.3 | Identification of a rare variant in 
SLC25A25 and other rare variants among the 
stone formers
Initial filtering of whole exome variants in Southampton 
identified two variants that fulfilled all selection criteria. One 
(rs41288957), in MAP3K5 (mitogen activated kinase 5, ASK1, 
OMIM 602448) had predicted low pathogenicity (SIFT 0.36, 
Polyphen: 0.002). The other (rs140777921) was in SLC25A25 
(dbSNP: chr9: 130868670G>C, (GRCh37.p13). This gene 
had been included in the candidate gene list because its ex-
pression (mRNA) in mouse kidney changed significantly with 
glyoxylate- induced calcium oxalate crystallization (Okada 
et al., 2009). The second round of filtering identified rare, 
predicted deleterious, variants in four genes expressed in kid-
neys, but with no reported association with stones to date: 
rs61729229 in VPS16 (vacuolar protein sorting 16 homolog; 
OMIM 608550), rs201441165 in an isoform of HAVCR1 
(Hepatitis A Virus Cellular Receptor 1; kidney injury molecule 
1, KIM- 1; OMIM 606518); rs15121559 in PLA2R1 (phospho-
lipase A2 receptor 1; OMIM 604939), and rs140419507 in 
PKP4 (plakophilin 4, catenin 4; OMIM 604276). The VPS16 
and HAVCR1 variants segregated with stone formers and not 
with non- stone formers while PLA2R1, MAP3K5, PKP4, and 
SLC25A25 (Figure 1a; Figure 2) showed incomplete segrega-
tion and were initially assigned lower priority.
WES screening of II- 2 and III- 3 in the Italian kindred 
identified the same rs140777921 variant of SLC25A25, 
which was verified by Sanger sequencing. The variant seg-
regated completely with stone formation (Figure 1b); and oc-
curred in only three of the 12 non- stone formers tested. The 
VPS16 variant was not associated with stones in this kindred.
F I G U R E  2  Segregation of gene variants & phosphaturia in the Southampton kindred. Rare variants in six genes identified by WES in stone 
formers II- 1, III- 5, and III- 7 were selected for their possible relevance to stone formation in this kindred. These variants were then analyzed for 
segregation across all 12 available family members using KASPar genotyping (KASP TM; LGC, Hoddesdon, Herts, UK). Orange indicates 
heterozygosity for the rare allele; green indicates the common allele
   | 7 of 14JABALAMELI Et AL.
3.4 | Comparisons with data from 
UK Biobank
Table 1  shows the frequencies of the rare variants of 
SLC25A25, VPS16, PLA2R1, MAP3K5, and PKP4 in the UK 
Biobank data for UK stone formers and non- stone formers. 
There were no statistically significant differences that with-
stood multiple testing correction between the allele frequen-
cies in the two groups, suggesting that these rare variants are 
not associated with stone disease at the population level.
3.5 | APC3 isoforms: selection of APC3b
APC3 has four isoforms generated by alternative gene splic-
ing, resulting in proteins with a common C- terminal region 
but with variations in the N- terminal region. Of these, mRNA 
for APC3a is widely expressed, highest in skeletal and heart 
muscle and pancreas, and moderate in the kidneys. mRNA for 
APC3b has a more restricted and lower expression, limited 
to kidneys, brain, and lungs. The amino acid sequences are 
identical from residue 54– 469 (APC3a) and 87– 503 (APC3b), 
and the main difference is that APC3a has three EF hands in 
the N- terminal region, whereas APC3b has four (del Arco & 
Satrústegui, 2004; Satrústegui et al., 2007). The rs140777921 
SNP is a G/C change in the SLC25A25 gene; Chr 9: 130868670 
G>C (GRCh37.P13 build). It is a missense variant which leads 
to substitution of histidine for glutamine in the transcripts of 
both the APC3a isoform (p.Gln315His in NM_052901.4) and 
the APC3b isoform (p.Gln349 His in NM_001006641.3).
It also overlaps four other SLC25A25 transcripts not ex-
pressed in the kidneys. It is rare (MAFgnomAD v3.1.1 = 0.0018; 
MAFSouthampton Database = 0.0033), at a highly conserved site 
(Phylop: 0.999532; Gerp++: 5.08), and predicted to be dele-
terious by in silico analysis (Combined Annotation Dependent 
Depletion, CADD v1.6: 26; Rentzsch et al., 2021). Three 
other stone- forming kindreds investigated by WES to date in 
the Southampton study do not have the variant. We opted to 
study APC3b because of the renal phenotype of the families 
and because this transcript was investigated previously in a 
study of TRPP2, a component of the renal polycystin 2 com-
plex (Hofherr et al., 2018).
3.6 | Modeling: The p.Gln349His variant 
could lead to destabilization of the domain 
structure of APC3b
APC3 alters the adenine nucleotide pool in the mitochondrial 
matrix in order to meet increased demand for cellular ATP 
and energy. It is activated by an increase in cytosolic calcium 
(Amigo et al., 2013; Aprille, 1993). The transporter has three 
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in the mitochondrial intermembrane space, which is involved 
in calcium regulation, (b) a loop domain with an amphipathic 
helix, and (c) a C- terminal mitochondrial carrier domain with 
six transmembrane and three matrix helices, which is in-
volved in transport of substrates (Harborne et al., 2015, 2017; 
Figure 3d). In the presence of calcium, the amphipathic helix 
is bound to the regulatory domain, allowing transport to occur 
(Harborne et al., 2015). In the calcium- free state, the amphip-
athic helix is released, binds to the carrier domain and inhibits 
transport (Fiermonte et al., 2004; Harborne et al., 2017).
The variant is in the carrier domain, and hence could po-
tentially affect the transport function of APC3b. The mutated 
Gln349 residue is conserved among all ATP- Mg/Pi carriers 
and is in an equivalent position to a highly conserved glutamate 
residue in human ADP/ATP carriers (Glu152 in human ade-
nine nucleotide translocase AAC1; Figure 3a). These residues 
interact with a positively charged amino acid located two resi-
dues downstream of a highly conserved Px[ED]xx[RK] motif of 
transmembrane helix 3 (H3; Miniero et al., 2011; Ruprecht et al., 
2014), Arg139 in AAC1 and Arg341 in APC3b. A glutamine to 
histidine substitution introduces a bulkier and less flexible side 
chain (Figure 3e). There are fewer backbone- dependent rotamers 
for the histidine side chain (3 out of 7) than for the glutamine side 
chain (8 out of 16), which could interact with Arg341. At the pH 
of the mitochondrial matrix (~pH 7.8), the imidazole ring of his-
tidine is likely to be partially charged (pKa ~6), and depending on 
the position of the deprotonated nitrogen, p.Gln349His is either 
2.9 Å or 4.6 Å distance from Arg341 (Li & Hong, 2011). The 
substitution could therefore disrupt the interaction with Arg341 
and destabilize the domain. Further, Gln349 precedes [YF]xG, a 
highly conserved motif at the N- terminus of the matrix helices 
involved in binding cardiolipin, which is important for mitochon-
drial carrier function (Klingenberg, 2009; Pebay- Peyroula et al., 
2003; Ruprecht et al., 2014, 2019; Figure S1). Disturbance of 
cardiolipin binding could be another destabilizing factor.
3.7 | The transport activity of the 
p.Gln349His variant is severely affected
To determine the effect of the variant on the transport activity, 
human wild- type and p.Gln349His APC3b were expressed in 
yeast mitochondria and purified. The protein purity and yield 
for the p.Gln349His variant were comparable to wild type, 
indicating that the variant did not impact the expression and 
targeting of the carrier (Figure S2). Thermal stability assays 
were used to test whether the p.Gln349His mutation had an 
effect on the apparent melting temperature (Tm), a relative 
measure of protein stability (Figure 4a). Both wild type and 
p.Gln349His gave an apparent Tm of 45.5℃ (three techni-
cal repeats) for the folded form in the presence of calcium. 
However, the variant displayed a higher baseline, a decreased 
derivative peak, and a series of folding intermediates at lower 
melting temperatures, indicative of a partially folded protein 
population. These observations agree with the notion that the 
protein itself is active, but that a part of the protein population 
might be unstable. Uptake assays were performed to assess 
the effect of the p.Gln349His variant on the transport activity. 
Purified wild type and p.Gln349His variant were pre- treated 
with the calcium chelator EGTA (10 mM) in order to mini-
mize free calcium in the sample, before being exchanged into 
assay buffer.
Wild- type and p.Gln349His APC3b were reconstituted 
into proteoliposomes and the uptake of radio- labelled ATP 
was monitored with and without calcium. In the presence 
of calcium, the uptake assays showed transport activity for 
both, but the overall activity of the p.Gln349His variant was 
only 21.6 ± 7% of the wild type (4 independent biological 
repeats). In the absence of calcium, transport by the p.Gln-
349His variant was similarly decreased to only 20.4 ± 5.3% 
residual activity (4 independent biological repeats; Figure 
4). These results indicate that the p.Gln349His variant im-
pacts the specific transport rate of ATP- Mg, without affect-
ing calcium regulation, which could be due to an unfolded 
subpopulation.
4 |  DISCUSSION
This study found that a rare autosomal dominant inherited 
missense variant of the gene for APC3, a mitochondrial 
ATP- Mg transporter, is associated with renal calcium stones 
with incomplete penetrance. The mutated gene encodes a 
dysfunctional protein.
F I G U R E  3  The glutamine to histidine substitution at position 349 in APC3b may compromise an intradomain interaction (a) Amino acid 
alignment of human ADP/ATP carrier paralogues 1– 4 (AAC1- 4), bovine ADP/ATP carrier 1 (AAC1) and ATP- Mg/Pi carrier paralogues (APC1, 
APC2, APC3a, APC3b, and APC4). The residues participating in the glutamine/glutamate- arginine interaction in the interface between the odd 
number helix (H3) and the matrix helix (h34) in domain 2 are indicated with green (arginine) and blue (glutamine/glutamate) diamonds. Lateral 
view of (b) bovine AAC1 (PDB: 1okc) and (c) APC3b from the membrane in the cytoplasmic- open state, showing the residues described in (a) 
The regulatory domain (cyan), amphipathic helix (purple), carrier domain (wheat), calcium ions (green spheres) are shown. Enlarged view of 
intradomain interactions of (d) AAC1 and (e) APC3b wild- type (top) and p.Gln349His (bottom). The arginine (green), glutamine/glutamate (blue) 
and the pathogenic variant p.Gln349His (pink), the interactions (gray dash) and distances (Å) are indicated. The tyrosine (green) in APC3b (not 
present in AAC1) may also contribute to the stabilization of domain 2. The model of APC3b was generated using MODELLER (Webb & Sali, 
2014) using the bovine AAC1 (PDB: 1okc) and the yeast ADP/ATP carrier structures (PDB: 4c9g, 4c9h, 4c9j, and 4c9q) as a template (Pebay- 
Peyroula et al., 2003; Ruprecht et al., 2014)
   | 9 of 14JABALAMELI Et AL.
APC3 mediates the net import or export of adenine nucle-
otides in mitochondria. Since it has calcium binding EF- hand 
motifs facing the extra- mitochondrial space, the activity of the 
transporter is regulated by cytosolic calcium. Hence APC3 can 
transduce calcium signals into the mitochondria without re-
quiring calcium entry into the matrix (del Arco & Satrústegui, 
2004; Fiermonte et al., 2004). Structural modeling shows that 
the affected residue in the p.Gln349His variant is positioned 
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in the interface between transmembrane helix 3 (H3) and the 
matrix helix (h34) interacting with Arg341, which might be 
important for stability of the transport protein. The transport 
activity of the p.Gln349His variant was significantly reduced 
to approximately one fifth of that of APC3b wild type, whereas 
the calcium regulation was unaffected. Thermostability assays 
show that a subfraction of the carrier population might be un-
folded, which would explain the lower specific activity. The 
in vivo activity of the mutant carrier paired with a wild type 
allele in the biallelic state, as in the stone patients, cannot be 
predicted from these experiments. However, heterozygous 
missense mutations of the gene for APC1, SLC25A24, present 
with a severe developmental phenotype (Ehmke et al., 2017; 
Writzl et al., 2017), indicating that mutations of this closely 
related protein have a dominant negative effect.
To date there are no reports of APC3 deficiency in hu-
mans and few reports from experimental animal models. 
In a study to address the effects of APC3 deficiency on 
energy metabolic efficiency, mice with global Slc25a25 
deletion were viable at birth, had small decreases in both 
fat and lean body mass after weaning, reduced exercise 
endurance and were resistant to diet- induced obesity. The 
kidneys were not examined and renal function was not in-
vestigated. Fibroblasts from Slc25a25−/− mouse embryos 
had decreased mitochondrial respiration and ATP, and 
decreased flux of Ca2+ across the endoplasmic reticulum 
F I G U R E  4  Effect of p.Gln349His on the thermal stability and transport activity of APC3b. (a) Thermostability profile (left), and its 
corresponding first derivative (right) of APC3b wildtype and p.Gln349His. (b) Schematic representation of proteoliposomes and the conditions 
tested. (c) A representative uptake curve showing the uptake of [14C]- ATP- Mg into proteoliposomes for APC3b wildtype (left) and pGln349His 
(right) with (red line) and without (black line) added calcium (1 mM). The error bars represent the standard deviation of four technical replicates. 
(d) Residual transport activity of APC3b p.Gln349His relative to APC3b wildtype, based on the initial transport rate and corrected for background 
binding with (red) and without (black) addition of 1 mM calcium. The error bars represent the standard deviation of four independent experiments, 
and the uptake curves are fitted with a one- phase association curve
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(Anunciado- Koza et al., 2011). There was no evidence of 
abnormally low exercise tolerance in the Southampton fam-
ily. The statin- induced muscle pain in one individual is of 
questionable relevance.
The SLC25A25 disease variant, associated with stones, 
could impair the ability of the mitochondrion to regulate the 
production of ATP. Many primary mitochondrial disorders 
may affect the kidneys, with a wide range of damaging ef-
fects. Stones and/or nephrocalcinosis have been reported in 
patients with mitochondrial depletion, in which dNTP pools 
may be reduced, in Kearns Sayer Syndrome, and in non- 
specific multiorgan mitochondrial disorders (Finsterer & 
Scorza, 2017).
The kidneys have a high energy requirement for transport 
of minerals and other components of the renal filtrate, with 
ATP consumption exceeding 2 kg/day (Walker, 2019). ATP 
depletion is likely to impact significantly on solute reabsorp-
tion throughout the nephron and this could lead to produc-
tion of lithogenic urine. Metabolomic investigation of human 
distal renal tubular cells in vitro found that ATP was sig-
nificantly reduced by SLC25A25 knock- down, and that con-
centrations of 42 metabolites changed significantly (Hofherr 
et al., 2018). The first tangible evidence for the importance 
of SLC25A25 as an energy supplier in the kidney in vivo 
is from a study investigating genome- wide gene expression 
(mRNA) in response to acute and prolonged metabolic ac-
idosis in proximal renal tubular cells from mice. Slc25a25 
was one of the genes with highest increase in expression in 
both conditions. Oxidative phosphorylation was the most up-
regulated cell pathway. It was proposed that in combination 
these responses supply ATP to fuel membrane transporter 
processes (Nowik et al., 2008).
Half of the Southampton family members, all with the 
variant, had hyperphosphaturia. This is common among stone 
formers, affecting around 30%. The explanation is unknown. 
Phosphate reabsorption occurs in the proximal tubules and is 
energy- dependent. In this kindred the rare SLC25A25 poly-
morphism might have contributed to hyperphosphaturia. 
Although hyperphosphaturia alone is unlikely to cause stones, 
it may do so in the presence of other urine abnormalities. The 
urinary profiles in 1998 did not include glucose, amino acids 
or low molecular weight proteins to investigate proximal tu-
bular dysfunction specifically. However, there is tangential 
evidence that two functions of the proximal tubular functions 
were not significantly compromised at this time: normal ci-
trate excretion indicates that the intracellular pH of the lumi-
nal epithelium was maintained within physiological limits, 
and excretion of oxalate was normal. This is regulated, in part, 
by proximal tubular carriers. Calcium was well absorbed and 
hypercalciuria was not a risk factor for stones in this family. 
No biochemical data are available for the Italian kindred.
As well as serving as an energy source, ATP is discharged 
extracellularly throughout the nephron for autocrine/paracrine 
purinergic signaling when renal cells are stretched by an in-
crease in cell volume due to hypo- osmolarity or to pressure 
changes in the renal tubules, or are stimulated by high flow 
rates through the tubular lumen bending cilia on the apical 
cell membranes. These stimuli trigger calcium release from 
intracellular stores, and ATP discharge through the plasma 
membrane, probably via pannexin channels (Burnstock et al., 
2014; Praetorius & Leipziger, 2013). The intracellular source 
for this burst of ATP for purinergic signaling is unknown. In 
polymorphonuclear neutrophils, it was shown to be the mito-
chondria (Bao et al., 2014). Recent studies by Hofherr et al., 
(2018) implicate APC3 in the cilia- triggered response to flow. 
They demonstrated that APC3 is one of the calcium- activated 
proteins that acts downstream of the polycystin- 2 (TRPP2) ion 
channel, a component of the polycystin complex in cilia. In ad-
dition, knock- down of Slc25a25 in zebra fish larvae disrupted 
normal body lateralization, typical of cilia dysfunction. In the 
distal renal tubules, purinergic stimulation normally protects 
the body from fluid overload by reducing sodium and water 
reabsorption, promoting a diuresis of dilute urine (Burnstock 
et al., 2014; Praetorius & Leipziger, 2013). A defective puri-
nergic response might increase the concentration of minerals 
at this site and the risk of crystallization. To date, this possi-
bility has received scant attention. The capacity to dilute urine 
was not tested in the Southampton family. Bile flow is sim-
ilarly stimulated by flow and hypotonicity, calcium- induced 
ATP release and purinergic signaling (Gradilone et al., 2007). 
It is possible that this response was reduced by the variant, 
contributing to gallstone formation in this kindred. Gallstone 
and kidney stone formation are independently associated 
(Taylor et al., 2011). Further studies in an animal model are re-
quired to explore the effects of the SLC25A25 variant in vivo.
In the families reported, the SLC25A25 mutation was not 
a fully penetrant cause of stone formation, indicating that 
in isolation it has only a modest effect on the susceptibility 
to stones. Other gene variants are likely to act as important 
modifiers to compound the risk, as in other complex poly-
genic disorders (Palsson et al., 2019; Pang et al., 2021). 
Possibilities in the Southampton family are those identified 
in VPS16 and HAVCR1 which code for a cell trafficking pro-
tein and the kidney injury molecule, KIM1, respectively, and 
the three considered less likely because of poor segregation 
with stones: PLA2R1, MAP3K5, and PKP4. Five large cross- 
sectional population GWAS studies have looked for associ-
ations between stones and common gene variants, two from 
Iceland (Oddsson et al., 2015; Thorleifsson et al., 2009), two 
from Japan (Tanikawa et al., 2019; Urabe et al., 2012) and 
one from the UK (Howles et al., 2019). The majority of the 
variants detected are non- coding, and functional studies to 
assess their relevance are lacking. It is notable that only six 
of the reported genes mapped closely to genes for membrane 
channels or transporters. The roles of many of the others in 
renal function or mineral turnover are currently unclear.
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The Analysis of data from the UK Biobank data set did 
not demonstrate a statistically significant association of the 
SLC25A25, VPS16, PLA2R1, MAP3K5, and PKP4 variants 
with stones. This can be explained by lack of statistical power 
for rare variant detection. Unless the polymorphism has a 
large effect on phenotype, extremely large study populations 
are required to demonstrate statistical associations for rare 
variants. In addition, due to the wide phenotypic heterogene-
ity of calcium stone disease, inaccurate reporting may have 
led to misclassification of the Biobank study participants into 
stone formers/non- stone formers. This would impact signifi-
cantly on the size of the small group with the variant, whilst 
having little effect on the large group with the common allele 
(Palsson et al., 2019; Pang et al., 2021).
This is the first report which links stones to a dysfunctional 
mitochondrial transporter. The exciting feature of this gene is 
that it is regulated by changes in intracellular calcium which, 
in turn, mediate cell signaling and ATP release. APC3 may 
be a key intermediary for adapting mitochondrial activity to 
molecular transport at the cell surface. Applied selectively to 
families or cohorts of individuals with a clearly defined clin-
ical and biochemical phenotype, WES has great capability to 
identify rare variants that contribute to stone risk which could 
not be predicted from our current limited understanding. It 
is essential that novel, unexpected associations, are explored 
by functional studies. Data and experience must be shared to 
progress our understanding of recurrent stone formation and 
prevention strategies.
ETHICAL COMPLIANCE
All the studies were conducted according to the Helsinki 
Declaration with ethical committee approval. Written and 
informed consent was obtained from all participants. The 
first Southampton Study was approved by the Southampton 
and South West Hampshire Research Ethics Committee 
(1997; Ref 322/970) and the second by the East of England- 
Cambridge Central Research Ethics Committee (2016; Ref 
16/EE/0293). The Italian study was performed according 
to the Italian National Bioethics Committee. UK Biobank 
has approval from the North West Multi- Centre Research 
Ethics Committee (11/NW/0382). The reported study 
(Epidemiology of Kidney Stone Disease) has UK Biobank 
Study ID 885.
ACKNOWLEDGMENTS
The authors thank Prof. Lesley Foulkes and Dr. Damian Griffin 
for their work with the Southampton family in 1998, Nicki 
Graham for assistance with DNA preparation and transport, 
Dr. Paul Cook for help with patient recruitment, Dr. Shane 
Palmer for the fermenters runs required to obtain material for 
the functional studies, and the families for their collaboration.
CONFLICT OF INTEREST
M.R. Jabalameli, F. Fitzpatrick, R. Colombo, S.A. Howles, 
E.R.S. Kunji, G. P. Leggatt, V. Walker, A. Wiberg, and S. 
Ennis, declare that they have no conflict of interest.
AUTHOR CONTRIBUTIONS
MRJ, GL, and SE undertook and interpreted the genomic 
studies in Southampton. RC investigated the Italian pedigree 
and coordinated genomic studies in his laboratory. ERSK 
undertook computational modeling of SLC25A25 and the 
disease variant, and FF and ERSK carried out the functional 
studies. SH coordinated the Biobank study and SH and AK 
analyzed the Biobank data. VW conceived and coordinated 
the Southampton study and drafted the manuscript. All 
Authors contributed to the final manuscript.
DATA AVAILABILITY STATEMENT
The data that supports the findings of this study are available 
in the supplementary material of this article.
REFERENCES
Amigo, I., Traba, J., González- Barroso, M. M., Rueda, C. B., Fernández, M., 
Rial, E., Sánchez, A., Satrústegui, J., & del Arco, A. (2013). Glucagon 
regulation of oxidative phosphorylation requires an increase in matrix 
adenine nucleotide content through Ca2+ activation of the mitochon-
drial ATP- Mg/Pi carrier SCaMC- 3. Journal of Biological Chemistry, 
288, 7791– 7802. https://doi.org/10.1074/jbc.M112.409144
Anunciado- Koza, R. P., Zhang, J., Ukropec, J., Bajpeyi, S., Koza, R. A., 
Rogers, R. C., Cefalu, W. T., Mynatt, R. L., & Kozak, L. P. (2011). 
Inactivation of the mitochondrial carrier SLC25A25 (ATP- Mg2+/
Pi transporter) reduces physical endurance and metabolic effi-
ciency in mice. Journal of Biological Chemistry, 286, 11659– 
11671. https://doi.org/10.1074/jbc.M110.203000
Aprille, J. R. (1993). Mechanism and regulation of the mitochondrial 
ATP- Mg/P(i) carrier. Journal of Bioenergetics and Biomembranes, 
25, 473– 481. https://doi.org/10.1007/BF011 08404
Bao, Y., Ledderose, C., Seier, T., Graf, A. F., Brix, B., Chong, E., & 
Junger, W. G. (2014). Mitochondria regulate neutrophil activation 
by generating ATP for autocrine purinergic signaling. Journal of 
Biological Chemistry, 289, 26794– 26803. https://doi.org/10.1074/
jbc.M114.572495
Bolger, A. M., Lohse, M., & Usadel, B. (2014). Trimmomatic: A flexi-
ble trimmer for Illumina sequence data. Bioinformatics, 30, 2114– 
2120. https://doi.org/10.1093/bioin forma tics/btu170
Braun, D. A., Lawson, J. A., Gee, H. Y., Halbritter, J., Shril, S., Tan, 
W., Stein, D., Wassner, A. J., Ferguson, M. A., Gucev, Z., Fisher, 
B., Spaneas, L., Varner, J., Sayer, J. A., Milosevic, D., Baum, M., 
Tasic, V., & Hildebrandt, F. (2016). Prevalence of monogenic 
causes in pediatric patients with nephrolithiasis or nephrocalcino-
sis. Clinical Journal of American Society of Nephrology, 11, 664– 
672. https://doi.org/10.2215/CJN.07540715
Burnstock, G., Evans, L. C., & Bailey, M. A. (2014). Purinergic signal-
ling in the kidney in health and disease. Purinergic Signalling, 10, 
71– 101. https://doi.org/10.1007/s1130 2- 013- 9400- 5
Coe, F. L., Evan, A., & Worcester, E. (2005). Kidney stone disease. The 
Journal of Clinical Investigation, 115(10), 2598– 2608. https://doi.
org/10.1172/JCI26662
   | 13 of 14JABALAMELI Et AL.
Collins, R. (2012). What makes UK Biobank special? The Lancet, 379, 
1173– 1174. https://doi.org/10.1016/S0140 - 6736(12)60404 - 8
Curhan, G. C., Willett, W. C., Rimm, E. B., & Stampfer, M. J. (1997). 
Family history and risk of kidney stones. Journal of the American 
Society of Nephrology, 8(10), 1568– 1573. https://doi.org/10.1681/
ASN.V8101568
Daga, A., Majmundar, A. J., Braun, D. A., Gee, H. Y., Lawson, J. 
A., Shril, S., Jobst- Schwan, T., Vivante, A., Schapiro, D., Tan, 
W., Warejko, J. K., Widmeier, E., Nelson, C. P., Fathy, H. M., 
Gucev, Z., Soliman, N. A., Hashmi, S., Halbritter, J., Halty, M., 
… Hildebrandt, F. (2018). Whole exome sequencing frequently 
detects a monogenic cause in early onset nephrolithiasis and 
nephrocalcinosis. Kidney International, 93, 204– 213. https://doi.
org/10.1016/j.kint.2017.06.025
De Pristo, M. A., Banks, E., Poplin, R., Garimella, K. V., Maguire, J. R., 
Hartl, C., Philippakis, A. A., Del Angel, G., Rivas, M. A., Hanna, 
M., & McKenna, A. (2011). A framework for variation discov-
ery and genotyping using next- generation DNA sequencing data. 
Nature Genetics, 43(5):491– 498. https://doi.org/10.1038/ng.806
del Arco, A., & Satrústegui, J. (2004). Identification of a novel human 
subfamily of mitochondrial carriers with calcium- binding do-
mains. Journal of Biological Chemistry, 279, 24701– 24713. 
https://doi.org/10.1074/jbc.M4014 17200
Ehmke, N., Graul- Neumann, L., Smorag, L., Koenig, R., Segebrecht, 
L., Magoulas, P., Scaglia, F., Kilic, E., Hennig, A. F., Adolphs, 
N., Saha, N., Fauler, B., Kalscheuer, V. M., Hennig, F., Altmüller, 
J., Netzer, C., Thiele, H., Nürnberg, P., Yigit, G., … Kornak, U. 
(2017). De Novo Mutations in SLC25A24 cause a craniosynostosis 
syndrome with hypertrichosis, progeroid appearance, and mito-
chondrial dysfunction. American Journal of Human Genetics, 101, 
833– 843. https://doi.org/10.1016/j.ajhg.2017.09.016
Fiermonte, G., de Leonardis, F., Todisco, S., Palmieri, L., Lasorsa, F. 
M., & Palmieri, F. (2004). Identification of the mitochondrial 
ATP- Mg/Pi transporter. Bacterial expression, reconstitution, 
functional characterization and tissue distribution. Journal of 
Biological Chemistry, 279, 30722– 30730. https://doi.org/10.1074/
jbc.M4004 45200
Finsterer, J., & Scorza, F. (2017). Renal manifestations of primary mi-
tochondrial disorders (Review). Biomedical Reports, 6, 487– 494. 
https://doi.org/10.3892/br.2017.892
Gambaro, G., Croppi, E., Coe, F., Lingeman, J., Moe, O., Worcester, 
E., Buchholz, N., Bushinsky, D., Curhan, G. C., Ferraro, P. M., 
Fuster, D., Goldfarb, D. S., Heilberg, I. P., Hess, B., Lieske, J., 
Marangella, M., Milliner, D., Preminger, G. M., Reis Santos, J. M., 
… Williams, J. C. (2016). Metabolic diagnosis and medical pre-
vention of calcium nephrolithiasis and its systemic manifestations: 
a consensus statement. Journal of Nephrology, 29(6), 715– 734. 
https://doi.org/10.1007/s4062 0- 016- 0329- y
Goldfarb, D. S., Avery, A. R., Beara- Lasic, L., Duncan, G. E., & 
Goldberg, J. (2019). A twin study of genetic influences on neph-
rolithiasis in women and men. Kidney International Reports, 4, 
535– 540. https://doi.org/10.1016/j.ekir.2018.11.017
Gradilone, S. A., Masyuk, A. I., Splinter, P. L., Banales, J. M., Huang, 
B. Q., Tietz, P. S., Masyuk, T. V., & LaRusso, N. F. (2007). 
Cholangiocyte cilia express TRPV4 and detect changes in lumi-
nal tonicity inducing bicarbonate secretion. Proceedings of the 
National Academy of Sciences of the United States of America, 
104(48), 19138– 19143. https://doi.org/10.1073/pnas.07059 64104
Halbritter, J., Baum, M., Hynes, A. M., Rice, S. J., Thwaites, D. T., 
Gucev, Z. S., Fisher, B., Spaneas, L., Porath, J. D., Braun, D. A., 
Wassner, A. J., Nelson, C. P., Tasic, V., Sayer, J. A., & Hildebrandt, 
F. (2015). Fourteen monogenic genes account for 15% of neph-
rolithiasis/nephrocalcinosis. Journal of the American Society of 
Nephrology, 26, 543– 551. https://doi.org/10.1681/ASN.20140 
40388
Harborne, S. P. D., King, M. S., Crichton, P. G., & Kunji, E. R. S. 
(2017). Calcium regulation of the human mitochondrial ATP/Mg/
Pi carrier SLC25A24 uses a locking pin mechanism. Scientific 
Reports, 7, 45383. https://doi.org/10.1038/srep4 5383
Harborne, S. P., Ruprecht, J. J., & Kunji, E. R. (2015). Calcium- induced 
conformational changes in the regulatory domain of the human 
mitochondrial ATP- Mg/Pi carrier. Biochimica Et Biophysica Acta, 
1847, 1245– 1253. https://doi.org/10.1016/j.bbabio.2015.07.002
Hofherr, A., Seger, C., Fitzpatrick, F., Busch, T., Michel, E., Luan, 
J., Osterried, L., Linden, F., Kramer- Zucker, A., Wakimoto, B., 
Schütze, C., Wiedemann, N., Artati, A., Adamski, J., Walz, G., 
Kunji, E. R. S., Montell, C., Watnick, T., & Köttgen, M. (2018). 
The mitochondrial transporter SLC25A25 links ciliary TRPP2 
signaling and cellular metabolism. PLoS Biology, 16, e2005651. 
https://doi.org/10.1371/journ al.pbio.2005651
Howles, S. A., & Thakker, R. V. (2020). Genetics of kidney stone 
disease. Nature Reviews Urology, 17(7), 407– 421. https://doi.
org/10.1038/s4158 5- 020- 0332- x
Howles, S. A., Wiberg, A., Goldsworthy, M., Bayliss, A. L., Gluck, 
A. K., Ng, M., Grout, E., Tanikawa, C., Kamatani, Y., Terao, C., 
Takahashi, A., Kubo, M., Matsuda, K., Thakker, R. V., Turney, B. 
W., & Furniss, D. (2019). Genetic variants of calcium and vitamin 
D metabolism in kidney stone disease. Nature Communications, 
10, 5175. https://doi.org/10.1038/s4146 7- 019- 13145 - x.
Klingenberg, M. (2009). Cardiolipin and mitochondrial carriers. 
Biochimica Et Biophysica Acta, 1788, 2048– 2058. https://doi.
org/10.1016/j.bbamem.2009.06.007
Li, S., & Hong, M. (2011). Protonation, tautomerization, and rotameric 
structure of histidine: a comprehensive study by magic- angle- 
spinning solid- state NMR. Journal of the American Chemical 
Society, 133, 1534– 1544. https://doi.org/10.1021/ja108 943n
Miniero, D. V., Cappello, A. R., Curcio, R., Ludovico, A., Daddabbo, 
L., Stipani, I., Robinson, A. J., Kunji, E. R., & Palmieri, F. (2011). 
Functional and structural role of amino acid residues in the ma-
trix alpha- helices, termini and cytosolic loops of the bovine mi-
tochondrial oxoglutarate carrier. Biochimica Et Biophysica Acta, 
1807:302– 310. https://doi.org/10.1016/j.bbabio.2010.12.005
Moe, O. W. (2006). Kidney stones: pathophysiology and medical man-
agement. The Lancet, 367, 333– 344. https://doi.org/10.1016/
S0140 - 6736(06)68071 - 9
Nowik, M., Lecca, M. R., Velic, A., Rehrauer, H., Brändli, A. W., & 
Wagner, C. A. (2008). Genome- wide gene expression profil-
ing reveals renal genes regulated during metabolic acidosis. 
Physiological Genomics, 32(3), 322– 334. https://doi.org/10.1152/
physi olgen omics.00160.2007
Oddsson, A., Sulem, P., Helgason, H., Edvardsson, V. O., Thorleifsson, 
G., Sveinbjörnsson, G., Haraldsdottir, E., Eyjolfsson, G. 
I., Sigurdardottir, O., Olafsson, I., Masson, G., Holm, H., 
Gudbjartsson, D. F., Thorsteinsdottir, U., Indridason, O. S., 
Palsson, R., & Stefansson, K. (2015). Common and rare vari-
ants associated with kidney stones and biochemical traits. Nature 
Commununications, 6, 7975. https://doi.org/10.1038/ncomm 
uns8975
Okada, A., Yasui, T., Hamamoto, S., Hirose, M., Kubota, Y., Itoh, 
Y., Tozawa, K., Hayashi, Y., & Kohri, K. (2009). Genome- wide 
14 of 14 |   JABALAMELI Et AL.
analysis of genes related to kidney stone formation and elimination 
in the calcium oxalate nephrolithiasis model mouse: detection of 
stone- preventive factors and involvement of macrophage activity. 
Journal of Bone and Mineral Research, 24, 908– 924. https://doi.
org/10.1359/jbmr.081245
Palsson, R., Indridason, O. S., Edvardsson, V. O., & Oddsson, A. (2019). 
Genetics of common complex kidney stone disease: insights from 
genome- wide association studies. Urolithiasis, 47, 11– 21. https://
doi.org/10.1007/s0024 0- 018- 1094- 2
Pang, H., Xia, Y., Luo, S., Huang, G., Li, X., Xie, Z., & Zhou, Z. (2021). 
Emerging roles of rare and low- frequency genetic variants in type 
1 diabetes mellitus. Journal of Medical Genetics, 58(5), 289– 296. 
https://doi.org/10.1136/jmedg enet- 2020- 107350
Pebay- Peyroula, E., Dahout- Gonzalez, C., Kahn, R., Trézéguet, V., 
Lauquin, G. J., & Brandolin, G. (2003). Structure of mitochondrial 
ADP/ATP carrier in complex with carboxyatractyloside. Nature, 
426, 39– 44. https://doi.org/10.1038/natur e02056
Praetorius, H. A., & Leipziger, J. (2013). Primary cilium- dependent 
sensing of urinary flow and paracrine purinergic signaling. 
Seminars in Cell & Developmental Biology, 24(1), 3– 10. https://
doi.org/10.1016/j.semcdb.2012.10.003
Prochaska, M. L., Taylor, E. N., & Curhan, G. C. (2016). Insights into 
nephrolithiasis from the Nurses’ Health Studies. American Journal 
of Public Health, 106, 1638– 1643. https://doi.org/10.2105/
AJPH.2016.303319
Purcell, S., Neale, B., Todd- Brown, K., Thomas, L., Ferreira, M. A. 
R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. 
J., & Sham, P. C. (2007). PLINK: A Tool Set for Whole- Genome 
Association and Population- Based Linkage Analyses. The 
American Journal of Human Genetics, 81(3), 559– 575. https://doi.
org/10.1086/519795
Rentzsch, P., Schubach, M., Shendure, J., & Kircher, M. (2021). CADD- 
Splice— improving genome- wide variant effect prediction using 
deep learning- derived splice scores. Genome Medicine, 13, 31. 
https://doi.org/10.1186/s1307 3- 021- 00835 - 9
Ruprecht, J. J., Hellawell, A. M., Harding, M., Crichton, P. G., McCoy, 
A. J., & Kunji, E. R. S. (2014). Structures of yeast mitochondrial 
ADP/ATP carriers support a domain- based alternating- access 
transport mechanism. Proceedings of the National Academy of 
Sciences of the United States of America, 111, E426– E434. https://
doi.org/10.1073/pnas.13206 92111
Ruprecht, J. J., King, M. S., Zögg, T., Aleksandrova, A. A., Pardon, E., 
Crichton, P. G., Steyaert, J., & Kunji, E. R. S. (2019). The molecu-
lar mechanism of transport by the mitochondrial ADP/ATP carrier. 
Cell, 176, 435– 447. https://doi.org/10.1016/j.cell.2018.11.025
Satrústegui, J., Pardo, B., & del Arco, A. (2007). Mitochondrial 
transporters as novel targets for intracellular calcium signaling. 
Physiological Reviews, 87, 29– 67. https://doi.org/10.1152/physr 
ev.00005.2006
Sayer, J. A. (2017). Progress in understanding the genetics of calcium- 
containing nephrolithiasis. Journal of the American Society of 
Nephrology, 28, 748– 759. https://doi.org/10.1681/ASN.20160 
50576
Tanikawa, C., Kamatani, Y., Terao, C., Usami, M., Takahashi, A., 
Momozawa, Y., Suzuki, K., Ogishima, S., Shimizu, A., Satoh, M., 
Matsuo, K., Mikami, H., Naito, M., Wakai, K., Yamaji, T., Sawada, 
N., Iwasaki, M., Tsugane, S., Kohri, K., … Matsuda, K. (2019). 
Novel risk loci identified in a genome- wide association study of 
urolithiasis in a Japanese population. Journal of the American 
Society of Nephrology, 30, 855– 864. https://doi.org/10.1681/
ASN.20180 90942
Taylor, E. N., Chan, A. T., Giovannucci, E. L., & Curhan, G. C. (2011). 
Cholelithiasis and risk of nephrolithiasis. Journal of Urology, 186, 
1882– 1887. https://doi.org/10.1016/j.juro.2011.06.067
Thorleifsson, G., Holm, H., Edvardsson, V., Walters, G. B., 
Styrkarsdottir, U., Gudbjartsson, D. F., Sulem, P., Halldorsson, 
B. V., de Vegt, F., Dancona, F. C., … den Heijer, M. (2009). 
Sequence variants in the CLDN14 gene associate with kidney 
stones and bone mineral density. Nature Genetics, 41, 926– 930. 
https://doi.org/10.1038/ng.404
Urabe, Y., Tanikawa, C., Takahashi, A., Okada, Y., Morizono, T., 
Tsunoda, T., Kamatani, N., Kohri, K., Chayama, K., Kubo, M., 
Nakamura, Y., & Matsuda, K. (2012). A genome- wide association 
study of nephrolithiasis in the Japanese population identifies novel 
susceptible loci at 5q35.3, 7p14.3, and 13q14.1. PLoS Genetics, 8, 
e1002541. https://doi.org/10.1371/journ al.pgen.1002541
Vezzoli, G., Terranegra, A., Arcidiacono, T., & Soldati, L. (2011). 
Genetics and calcium nephrolithiasis. Kidney International, 80, 
587– 593. https://doi.org/10.1038/ki.2010.430
Walker, V. (2019). Phosphaturia in kidney stone formers: still an 
enigma. Advances in Clinical Chemistry, 90, 133– 196. https://doi.
org/10.1016/bs.acc.2019.01.004
Walker, V., & Griffin, D. G. (2015). Renal calcium and urate han-
dling and diet in idiopathic stone formers. In M. Schneider (Ed). 
Neprolithiasis: Risk factors, treatment and prevention (pp. 67– 
103). Nova Biomedical. ISBN:978- 1- 63482- 134- 6.
Walker, V., Stansbridge, E. M., & Griffin, D. G. (2013). Demography 
and biochemistry of 2800 patients from a renal stones clinic. Annals 
of Clinical Biochemistry, 50, 127– 139. https://doi.org/10.1258/
acb.2012.012122
Webb, B., & Sali, A. (2014). Comparative protein structure modeling 
using MODELLER. Current Protocols in Bioinformatics, 47(1), 
1– 5. https://doi.org/10.1002/04712 50953.bi050 6s47
Writzl, K., Maver, A., Kovačič, L., Martinez- Valero, P., Contreras, 
L., Satrustegui, J., Castori, M., Faivre, L., Lapunzina, P., van 
Kuilenburg, A. B. P., Radović, S., Thauvin- Robinet, C., Peterlin, 
B., del Arco, A., & Hennekam, R. C. (2017). De Novo mutations in 
SLC25A24 cause a disorder characterized by early aging, bone dys-
plasia, characteristic face, and early demise. The American Journal 
of Human Genetics, 101, 844– 855. https://doi.org/10.1016/j.
ajhg.2017.09.017
SUPPORTING INFORMATION
Additional supporting information may be found online in 
the Supporting Information section.
How to cite this article: Jabalameli, M. R., 
Fitzpatrick, F. M., Colombo, R., Howles, S. A., 
Leggatt, G., Walker, V., Wiberg, A., Kunji, E. R. S., 
& Ennis, S. (2021). Exome sequencing identifies a 
disease variant of the mitochondrial ATP- Mg/Pi 
carrier SLC25A25 in two families with kidney stones. 
Molecular Genetics & Genomic Medicine, 00, e1749. 
https://doi.org/10.1002/mgg3.1749
